Food Matters Live Podcast · Food Matters Live

Navigating GLP-1 and the future of positive nutrition

·54 min·2 clips

Holland and Barrett’s Dr Tarrant calls GLP-1 “a trend breaker” and says the first use case is only the “beachhead.”

The recording opens live from Food Matters Live in Rotterdam. Anthony Zahra introduces the session as a look at innovations, big ideas, and the people pushing food forward. He frames GLP-1 as a market question as much as a health one. The central issue is whether the drugs are a passing fad or a sign of deeper change. The panel is presented in partnership with Rousselot. Speakers then focus on how people on GLP-1 medication often change food preferences and eating habits. That shift is treated as both a challenge and a chance for the food industry. Jeffrey Rousselot starts by looking at consumer behavior through the lens of wellness goals. He says people are aligning their spending with what they think will help them feel better. Protein comes up repeatedly. Sugar reduction comes up too. Alcohol reduction becomes another major thread. The discussion notes that some studies show a substantial drop in alcohol consumption. That scale makes substitutes and alternatives commercially interesting. The panel then moves to premiumization. The argument is that GLP-1 consumers may be willing to spend more on good quality products when the ingredient story clearly supports their goals. Restaurants enter the conversation next. More flexible operators are described as adapting menus to a GLP-1-friendly diet. At the same time, they are said to be doubling down on the social and experiential side of dining out. The speakers stress that people still want theatre, company, and an experience, not just food as fuel. That idea is summed up through the phrase eatainment. The panel then sketches a simple lifecycle for the GLP-1 consumer. There is onboarding, then maintenance, then mastery. The speakers suggest the market is still early in that path. The discussion stays cautious about certainty. It keeps coming back to what the evidence can and cannot yet support. The conversation broadens again to supplements and the idea that products can support the body’s own GLP-1 response. In that stretch, inflammation and cardiovascular benefits are mentioned alongside the commercial language around microdosing. The panel uses that term as a marketing way of saying people may need less. The closing argument pushes back against reducing GLP-1 to weight management alone. The larger point is that the trend is already shaping food, supplement, and dining strategies. The episode ends by returning to the practical implications for the industry and by reminding listeners about future Food Matters Live events in London and Rotterdam.

As heard by us

A clear read on how GLP-1 is reshaping food demand, reformulation, and premiumization.

The episode frames GLP-1 less as a fleeting wellness story and more as a change in consumer behavior. Listeners hear how eating habits, buying patterns, and attitudes toward protein, sugar, and alcohol are shifting, with the panel consistently linking those changes to…

Read the full review in PlayNext →

Why you'd press play

You want the market read on GLP-1's food fallout.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Food Matters Live Podcast